A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

December 29, 2016

Primary Completion Date

June 12, 2021

Study Completion Date

January 12, 2022

Conditions
Type 2 Diabetes
Interventions
DRUG

Dulaglutide

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (61)

1089

Heim Pal Gyermekkorhaz, Budapest

11472

King Saud University Hospital, Riyadh

12769

King Salman bin Abdulaziz Hospital - Diabetic Center, Riyadh

15224

Childrens Hospital of Pittsburgh, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

20010

Children's National Medical Center, Washington D.C.

23758

RED-Institut GmbH, Oldenburg in Holstein

25302

CAMC Institute, Charleston

27834

ECU Pediatric Specialty Care, Greenville

32803

Florida Center for Endocrinology & Metabolism, Orlando

35233

University of Alabama Birmingham, Birmingham

45116

Centro de Inv. Medica de Occidente, SC, Zapopan

45229

Cincinnati Childrens Hospital Medical Center, Cincinnati

46202

Indiana University Health Hospital, Indianapolis

55139

Ondokuz Mayis University Medical Faculty, Samsun

56727

Praxis Dr. med. Landers, Mayen

60612

University of Illinois at Chicago, Chicago

64108

Children's Mercy Hospital, Kansas City

64710

Centro Medico San Francisco, Monterrey

66386

Zentrum für klinische Studien, Sankt Ingbert

72190

Hospital Angeles Puebla, Puebla City

75019

Hopital Robert Debre, Paris

81620

Duzce University Medical Faculty, Düzce

83712

St. Luke's Regional Medical Center, Boise

85724

University of Arizona, Tucson

89249

Cli-nica Hospital Cemain, Tampico

90027

Division of Endocrinology, Diabetes, and Metabolism, Los Angeles

91910

Arke Estudios Clinicos S.A. de C.V., Veracruz

92123

Rady Childrens Hospital - San Diego, San Diego

92805

Advanced Research Center, Anaheim

92868

Childrens Hospital of Orange County, Orange

94275

Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre, Le Kremlin-Bicêtre

94592

Touro University, Vallejo

95148

JC Cabaccan, San Jose

95821

Center of Excellence in Diabetes & Endocrinology, Sacramento

98105

Seattle Children's Hospital Research Foundation, Seattle

98405

Multicare Health System, Tacoma

110060

Sir Ganga Ram Hospital, New Delhi

160012

Post Graduate Institute of Medical Education & Research, Chandigarh

221005

Banaras Hindu University - BHU, Varanasi

380007

Dr Jivraj Mehta Smarak Health Foundation Bakeri Medical Research Centre, Ahmedabad

411004

Deenanath Mangeshkar Hospital & Research Centre, Pune

560017

Manipal Hospital, Bangalore

560054

M S Ramaiah Medical College Hospital, Bangalore

700017

Park Clinic, Kolkata

700054

Apollo Gleneagles Hospitals Kolkata, Kolkata

70808-4124

Pennington Biomedical Research Center, Baton Rouge

20211-340

Instituto Estadual de Diabetes e Endocrinologia, Rio de Janeiro

90430-001

Centro de Pesquisas em Diabetes, Porto Alegre

91350-200

Instituto da Criança com Diabetes, Porto Alegre

13034-685

Hospital PUC-CAMPINAS, Campinas

14051-140

Hospital das Clinicas da FMRP, Ribeirão Preto

01228-200

CPCLIN, São Paulo

05403-000

Hospital da Clinicas da Faculdade de Medicina da USP, São Paulo

04022-001

UNIFESP - Escola Paulista de Medicina, São Paulo

03810

Health Pharma Professional Research, S.A. de C.V., Mexico City

00959

Centro de Diabetes y Endocrinologia Pediatrica de PR, Bayamón

06100

Ankara University Medicine Hospital, Ankara

06080

Sami Ulus Education & Research Hospital, Ankara

L14 5AB

Alder Hey Children's Hospital, Liverpool

LS9 7TF

St James's University Hospital, Leeds

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02963766 - A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes | Biotech Hunter | Biotech Hunter